Martin Nicklasson new CEO and President of Biovitrum
The Board of Biovitrum has appointed Martin Nicklasson as the new CEO and
President.
Martin Nicklasson, 52, is currently the CEO of AstraZeneca AB. He is also a
member of the executive management of AstraZeneca Plc., where as Executive Vice
President, he is head of Global Marketing.
Martin Nicklasson has previously held a number of leadership positions within
AstraZeneca, Kabi Pharmacia and Astra. He has a degree in Pharmacy, and a Ph.D.
in Pharmaceutical Science. Since 1985 he has been an associate professor at the
Faculty of Pharmacy at Uppsala University.
“Martin Nicklasson is a skilled and experienced executive, and with his
background he will be a great asset for Biovitrum. We will continue to focus on
strengthening Biovitrum's position as a leading European biopharma company, and
Martin has the requisite experience for leading the development of our broad and
balanced product portfolio, and further strengthening Biovitrum's commercial
position. I would also like to express my appreciation for Mats Pettersson, our
CEO who is now moving on. Under his leadership, Biovitrum has made a fantastic
journey, and the course Mats has set has been critical for getting Biovitrum to
the advantageous position it has today,” says Biovitrum's Chairman Håkan Åström.
“After my six years as a CEO, it feels good to be able to step back at a point
when the company is standing strong, with excellent prospects for the future. It
has been a fantastic time, and I believe that Biovitrum's strong development
will continue under Martin Nicklasson's leadership,” says Biovitrum's parting
CEO Mats Pettersson.
“As the new CEO, I am very eager to get started with the plans to further
develop Biovitrum as a new Swedish biopharma company. Today the company has a
solid position with many opportunities to be even stronger in the future. I have
followed Biovitrum for a number of years, and my impression is that the company
has a rich potential. Biovitrum has also conducted a successful public listing,
and I see it as a key objective to further develop the company and its personnel
and thus create value for the company's shareholders,” says Martin Nicklasson,
Biovitrum's next CEO.
Mats Pettersson will remain as CEO until Martin Nicklasson assumes his position
on May 14.
For more information, please contact:
Biovitrum AB (publ)
Håkan Åström, Chairman of the Board
Cell phone: +46 70 374 72 13
hakanastrom@aol.com
Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 2085, Cell phone: +46 73 433 20 85
annakarin.kallen@biovitrum.com
About Biovitrum
Biovitrum is one of the largest biopharma companies in Europe. With operations
in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals
for unmet medical needs both for common diseases and conditions that affect
smaller patient populations. Biovitrum has a broad and balanced R&D portfolio
with several projects in clinical and preclinical phases for the treatment of
obesity, diabetes, inflammation and eye and blood diseases as well as a number
of well defined niche indications. Biovitrum develops and produces protein-based
drugs on a contractual basis and markets a range of specialist pharmaceuticals
primarily in the Nordic countries. Biovitrum has revenues of approximately SEK
1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock
Exchange since September 15, 2006. For more information see www.biovitrum.com/.
